Showing 201 - 210 of 130,277
Persistent link: https://www.econbiz.de/10001583136
Persistent link: https://www.econbiz.de/10000577227
Persistent link: https://www.econbiz.de/10011293117
Persistent link: https://www.econbiz.de/10010442786
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10013139118
Reference prices constitute a main determinant of patient health care reimbursement in many countries. We study the effects of a change from an "external" (based on a basket of prices in other countries) to an "internal" (based on comparable domestic products) reference price system.We find that...
Persistent link: https://www.econbiz.de/10013085071
We determine the optimal health policy mix when the average utility of patients increases with the supply of drugs available in a therapeutic class. Health risk coverage rely on two instruments, copayment and reference pricing, that affect the supported risk composed by health expenses and...
Persistent link: https://www.econbiz.de/10013086413
arrangements. I illustrate my argument with the analysis of the implementation of rigid prices for reimbursed pharmaceuticals in …
Persistent link: https://www.econbiz.de/10013089776
This paper uses macro-level data between 1997 and 2008 to evaluate the effects of China's pharmaceutical price regulations. We find that these regulations had short-run effects on medicine price indices, reducing them by less than 0.5 percentage points. The effects could have been slightly...
Persistent link: https://www.econbiz.de/10013066440